ReviewSubstance abuse and rehabilitation2025
Benzodiazepine Use Among Individuals with Opioid Use Disorder: A Narrative Review.
Review in Substance abuse and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neuropsychiatric-pharmacologic synergy: interaction between psychiatric polypharmacy and cancer treatment-related neurotoxicity.Oxford medical case reports · 2026Article
- Rational Use of Benzodiazepines in Modern Healthcare: Evidence-Based Strategies.Healthcare (Basel, Switzerland) · 2026Review
- The Real-World Safety Profile of Temazepam: A 20-Year Pharmacovigilance Analysis Based on the Large-Scale FAERS Database.CNS neuroscience & therapeutics · 2026Article
- Benzodiazepine Use Among Patients Receiving Methadone Maintenance Treatment: A Descriptive Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concomitant use of benzodiazepines (BZDs) among individuals with opioid use disorder (OUD) is highly prevalent, with a rapid annual increase in overdose-related deaths. The co-use of BZDs is a significant predictor of opioid overdose. In the absence of other drugs, BZDs are rarely the sole cause of death. Prolonged BZD use frequently results in the rapid development of tolerance and dependence. A strong association has also been established between BZD misuse and depression. Moreover, chronic BZD exposure is linked to cognitive impairments, psychomotor disturbance, delirium, and an increased risk of falls, fractures, injuries, and traffic accidents. Outpatient clinicians should routinely screen for concurrent BZD use and exercise caution in prescribing. Timely interventions-including patient education, gradual discontinuation, psychological therapies, and skills-based training-are critical to mitigating harm and improving prognosis. In addition, Traditional Chinese Medicine(TCM), including herbal prescriptions and acupuncture, may serve as promising non-addictive alternatives for the management of anxiety, insomnia, and withdrawal-related symptoms. Strengthening multifaceted efforts will be crucial for reducing the burden of BZD use and improving treatment outcomes in OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.